O	0	8	Adequate
O	9	21	locoregional
O	22	31	treatment
O	32	35	for
O	36	41	early
O	42	48	breast
O	49	55	cancer
O	56	59	may
O	60	67	prevent
O	68	77	secondary
O	78	91	dissemination
O	91	92	.

O	93	95	To
O	96	103	analyze
O	104	113	different
O	114	120	events
O	121	125	that
O	126	135	determine
O	136	141	event
O	141	142	-
O	142	146	free
O	147	155	survival
O	156	157	(
O	157	160	EFS
O	160	161	)
O	162	164	in
O	165	166	a
O	167	177	randomized
O	178	183	trial
O	184	186	on
B-intervention	187	195	adjuvant
I-intervention	196	208	radiotherapy
O	209	211	in
B-eligibility	212	217	early
I-eligibility	218	224	breast
I-eligibility	225	231	cancer
I-eligibility	232	240	patients
I-eligibility	241	245	with
I-eligibility	246	250	more
I-eligibility	251	255	than
I-eligibility	256	258	15
I-eligibility	259	264	years
I-eligibility	265	267	of
I-eligibility	268	274	follow
I-eligibility	274	275	-
I-eligibility	275	277	up
I-eligibility	278	288	evaluation
O	288	289	.

O	290	293	The
O	294	299	trial
O	300	308	included
B-total-participants	309	312	960
O	313	321	patients
O	322	326	with
O	327	328	a
O	329	339	unilateral
O	339	340	,
O	341	349	operable
O	350	356	breast
O	357	363	cancer
O	363	364	.

O	365	372	Surgery
O	373	382	consisted
O	383	385	of
O	386	387	a
O	388	396	modified
O	397	404	radical
O	405	415	mastectomy
O	415	416	.

O	417	420	The
O	421	426	trial
O	427	435	compared
O	436	441	three
O	442	446	arms
O	446	447	,
O	448	450	as
O	451	458	follows
O	458	459	:
O	460	472	preoperative
O	473	485	radiotherapy
O	485	486	,
O	487	500	postoperative
O	501	513	radiotherapy
O	513	514	,
O	515	518	and
B-control	519	521	no
I-control	522	530	adjuvant
I-control	531	540	treatment
O	540	541	.

O	542	548	Events
O	549	553	were
O	554	562	analyzed
O	563	565	by
O	566	567	a
O	568	577	competing
O	577	578	-
O	578	582	risk
O	583	591	approach
O	591	592	.

O	593	594	A
O	595	607	proportional
O	608	615	hazards
O	616	624	multiple
O	625	635	regression
O	636	641	model
O	642	645	was
O	646	650	used
O	651	653	to
O	654	661	analyze
O	662	665	the
O	666	673	effects
O	674	676	of
O	677	689	radiotherapy
O	690	692	on
O	693	696	the
O	697	701	risk
O	702	704	of
O	705	712	distant
O	713	723	metastasis
O	723	724	.

O	725	732	Similar
O	733	741	analyses
O	742	746	were
O	747	756	performed
O	757	767	separately
O	768	771	for
O	772	776	node
O	776	777	-
O	777	785	negative
O	786	787	[
O	787	788	N
O	788	789	(
O	789	790	-
O	790	791	)
O	791	792	]
O	793	796	and
O	797	801	node
O	801	802	-
O	802	810	positive
O	811	812	[
O	812	813	N
O	813	814	(
O	814	815	+
O	815	816	)
O	816	817	]
O	818	826	patients
O	827	829	in
O	830	833	the
O	834	837	two
O	838	844	groups
O	845	849	that
O	850	853	did
O	854	857	not
O	858	865	include
O	866	878	preoperative
O	879	891	radiotherapy
O	891	892	.

O	893	905	Radiotherapy
O	906	914	produced
O	915	916	a
O	917	925	fivefold
O	926	934	decrease
O	935	937	of
O	938	941	the
B-outcome	942	946	risk
I-outcome	947	949	of
I-outcome	950	955	local
I-outcome	956	966	recurrence
O	967	968	(
O	968	969	P
O	970	971	<
O	972	973	.
O	973	977	0001
O	977	978	)
O	978	979	.

O	980	982	In
O	983	984	N
O	984	985	(
O	985	986	+
O	986	987	)
O	988	996	patients
O	996	997	,
O	998	1011	postoperative
O	1012	1024	radiotherapy
O	1025	1034	decreased
O	1035	1038	the
B-outcome	1039	1043	risk
I-outcome	1044	1046	of
I-outcome	1047	1054	distant
I-outcome	1055	1068	dissemination
O	1069	1070	(
O	1070	1078	relative
O	1079	1083	risk
O	1083	1084	,
O	1085	1086	0
O	1086	1087	.
O	1087	1089	63
O	1089	1090	)
O	1090	1091	.

O	1092	1096	When
O	1097	1102	local
O	1103	1113	recurrence
O	1114	1117	was
O	1118	1128	introduced
O	1129	1131	in
O	1132	1135	the
O	1136	1141	model
O	1142	1144	as
O	1145	1146	a
O	1147	1151	time
O	1151	1152	-
O	1152	1161	dependent
O	1162	1171	covariate
O	1171	1172	,
O	1173	1177	this
O	1178	1184	factor
O	1185	1188	was
O	1189	1199	predictive
O	1200	1202	of
O	1203	1210	distant
O	1211	1224	dissemination
O	1225	1226	(
O	1226	1227	P
O	1228	1229	<
O	1230	1231	.
O	1231	1235	0001
O	1235	1236	)
O	1237	1240	and
O	1241	1250	nullified
O	1251	1254	the
O	1255	1261	effect
O	1262	1264	of
O	1265	1278	postoperative
O	1279	1291	radiotherapy
O	1291	1292	.

O	1293	1297	This
O	1298	1305	finding
O	1306	1314	suggests
O	1315	1319	that
O	1320	1323	the
O	1324	1332	decrease
O	1333	1335	of
O	1336	1343	distant
O	1344	1354	metastases
O	1355	1358	was
O	1359	1366	related
O	1367	1369	to
O	1370	1373	the
O	1374	1384	prevention
O	1385	1387	of
O	1388	1393	local
O	1394	1404	recurrence
O	1404	1405	.

O	1406	1407	A
O	1408	1415	similar
O	1416	1422	effect
O	1423	1426	was
O	1427	1432	found
O	1433	1435	in
O	1436	1442	models
O	1443	1447	that
O	1448	1452	used
B-outcome-Measure	1453	1460	overall
I-outcome-Measure	1461	1469	survival
O	1470	1472	as
O	1473	1475	an
O	1476	1479	end
O	1480	1485	point
O	1485	1486	.

O	1487	1491	This
O	1492	1497	study
O	1498	1503	shows
O	1504	1508	that
O	1509	1523	postmastectomy
O	1524	1536	radiotherapy
O	1537	1539	in
O	1540	1541	N
O	1541	1542	(
O	1542	1543	+
O	1543	1544	)
O	1545	1551	breast
O	1552	1558	cancer
O	1559	1567	patients
O	1568	1571	may
O	1572	1580	decrease
O	1581	1584	the
O	1585	1592	distant
O	1593	1603	metastasis
O	1604	1608	rate
O	1609	1611	by
O	1612	1622	preventing
O	1623	1628	local
O	1629	1640	recurrences
O	1641	1644	and
O	1645	1649	thus
O	1650	1658	avoiding
O	1659	1668	secondary
O	1669	1682	dissemination
O	1682	1683	.
